Breakthrough in Glioma Treatment: New Drug Delays Progression of Deadly Brain Cancer — Study is the first clinica |
A novel targeted therapy drug, vorasidenib, has been shown to more than double the progression-free survival in patients with a subtype of glioma, according to an international study co-led by UCLA. By inhibiting mutant IDH1/2, the drug delays chemotherapy and radiation by almost 17 months, providing a breakthrough treatment for this deadly brain tumor.
In a study of 331 people with the disease, the drug was effective in lengthening the period of time before the patients’ cancer worsened, and with no observed adverse effects. The team found the drug vorasidenib more than doubled progression-free survival in people with recurrent grade 2 glioma with IDH1 and IDH2 mutations. Compared with people who received a placebo, those who took vorasidenib went for nearly 17 more months without their cancer worsening, delaying the time before they needed to begin chemotherapy and radiation.and presented on June 4, 2023, at the annual meeting of the American Society Clinical Oncology in Chicago.
Vorasidenib is classified as a dual inhibitor of mutant IDH1/2, meaning that it prevents the formation and accumulation of the onco-metabolite 2-Hydroxyglutarate, or 2-HG, that occurs when genetically altered versions of two enzymes, IDH1 and IDH2, are present in a tumor. 2-HG is thought to be responsible for the formation and maintenance of IDH-mutant gliomas.
While there has been great progress in using targeted therapies to treat many types of cancer, development of targeted therapies for brain tumors has been especially challenging because of the difficulty of getting through the blood-brain barrier. Vorasidenib is a brain-penetrant inhibitor, which means that it has the ability to cross the blood-brain barrier.
The disease progressed in just 28% of people receiving vorasidenib, compared to 54% of those receiving placebos. And as of September 2022, which was 30 months after the study began, 72% of patients who were in the vorasidenib group were still taking the drug and their disease had not progressed.
Indonesia Berita Terbaru, Indonesia Berita utama
Similar News:Anda juga dapat membaca berita serupa dengan ini yang kami kumpulkan dari sumber berita lain.
Treatment Breakthrough for an Intractable Brain CancerA new drug helped stall brain-cancer growth in a study of glioma patients, a breakthrough in a field that has made little progress in decades
Baca lebih lajut »
Eating disorder patients say punitive, threatening methods at Denver treatment center left them with new traumaSeven former patients and three former staff members staff described to The Denver Post a punitive and traumatic environment at the Denver-based Eating Recovery Center, one of the largest treatment providers in the country.
Baca lebih lajut »
Cancer vaccines poised to unlock 'new treatment paradigm' with Merck/Moderna dataAdding an experimental mRNA-based vaccine from Moderna Inc and Merck & Co reduced the risk that the most deadly skin cancer would spread by 65% over treatment with an immunotherapy alone in a midstage trial, the companies reported on Monday.
Baca lebih lajut »
Brown Fat Breakthrough Could Lead to Novel Obesity TreatmentsUnderstanding of the mechanism by which brown fat burns off calories as heat offered potential new treatments for obesity and diabetes, researchers said.
Baca lebih lajut »
For Rangers' Josh Jung, a breakthrough and a comebackAfter a shoulder injury made it seem like MacArthur alum Josh Jung's baseball career was cursed, his 'relentless' approach has led to a stellar rookie season with the Texas Rangers.
Baca lebih lajut »
No breakthrough in NATO-Turkey talks about Sweden joiningNATO Secretary-General Jens Stoltenberg made no breakthrough on Sunday in talks about Sweden’s membership in the military organization with Turkish President Recep Tayyip Erdogan, with officials from the two countries to meet in just over a week to try to bridge their differences.
Baca lebih lajut »